FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table of Contents<br />
Prior to <strong>20</strong>08, the Group acquired several small regional pharmacy chains in Mexico and in May <strong>20</strong>08, <strong>Grupo</strong> <strong>Casa</strong> <strong>Saba</strong> acquired Drogasmil, a Brazilian pharmacy chain<br />
that currently operates in the states of São Paulo and Río <strong>de</strong> Janeiro. This acquisition was the Company’s first outsi<strong>de</strong> of Mexico.<br />
On September 30, <strong>20</strong>10, we successfully completed the Ten<strong>de</strong>r Offer through which we acquired 97.8% of Farmacias Ahumada’s capital stock. Given that FASA owns<br />
95.62% of Farmacias Benavi<strong>de</strong>s’s outstanding capital stock, once we acquired FASA’s shares, the Group indirectly acquired a controlling participation in Farmacias Benavi<strong>de</strong>s. We<br />
consi<strong>de</strong>r that by means of this transaction we are now the largest drugstore chain in Latin America and one of the largest distributors of consumer and pharmaceutical products in the<br />
region, with a platform of more than 1,500 pharmacies across Mexico, Brazil, Chile and Peru at the end of <strong>20</strong>11. See “—History and Development of the Company” and “Item 10.<br />
Additional Information—Material Contracts”.<br />
We believe the Acquisition is creating value for our sharehol<strong>de</strong>rs. These synergies provi<strong>de</strong> ad<strong>de</strong>d strength to the Company by significantly increasing its size as one<br />
of the main distributors and vendors of pharmaceutical, health, beauty, personal care and general merchandise products and giving us a larger international presence. As a result of the<br />
Acquisition, we also seek to reinforce our regional growth strategy through a proven and wi<strong>de</strong> multi-country platform.<br />
We believe that, although the initial costs of growing our retail operations, may be high and our profitability and financial structure may be temporarily affected, the<br />
retail pharmacy business will contribute to our long-term growth in both the retail and distribution markets.<br />
By the end of <strong>20</strong>11, we had successfully completed the integration of FASA into our corporate structure, although there are still opportunities to continue increasing<br />
our efficiency levels going forward. In <strong>20</strong>12, we seek to improve both the efficiency and our profitability of our Retail division though a significant expansion plan in Mexico, Chile and<br />
Brazil, followed by the application of strict cost control measures and intelligent purchasing methodologies.<br />
In or<strong>de</strong>r to concentrate our efforts on the expansion in Mexico, Brazil and Chile, on January 19, <strong>20</strong>12, FASA Investment Limitada, a subsidiary of <strong>Grupo</strong> <strong>Casa</strong> <strong>Saba</strong>,<br />
sold its shareholding in the social capital of Famacias Peruanas, S.A. and Droguería La Victoria, S.A.C., subsidiary companies of FASA through which a chain of drugstores was<br />
operated in Peru.<br />
In line with our strategy, this year, we increased the number of stores in our two main markets, Chile and Mexico. In Chile, we ad<strong>de</strong>d several new stores in key areas<br />
which will help us compete more effectively in the marketplace. In Mexico, we grew the number of stores in the Benavi<strong>de</strong>s chain and entered the State of Mexico and Mexico City<br />
markets. This expansion will enable us to wi<strong>de</strong>n our overall client base and increase our presence in this market.<br />
Strengthening the Company’s Financial Position<br />
By the end of <strong>20</strong>11, our interest-bearing liabilities totaled Ps. 12,556.5 million and our net <strong>de</strong>bt was Ps. 10,246.1 million, a large part of which was related to the<br />
acquisition of FASA in the fourth quarter of <strong>20</strong>10.<br />
On August 11, <strong>20</strong>11, <strong>Grupo</strong> <strong>Casa</strong> <strong>Saba</strong> successfully refinanced the bridge loan that was executed on August 30, <strong>20</strong>10 in the amount of Ps. 7,732.9 in or<strong>de</strong>r to acquire<br />
FASA, as well as the collateral package that was executed to guarantee its obligations un<strong>de</strong>r the loan. The loan term was exten<strong>de</strong>d for seven years, and is divi<strong>de</strong>d into two<br />
tranches. The shorter average life tranche has an average margin of TIIE (the Mexican Interbank Balance Interest Rate) + 2.25% while the longer average life tranche’s margin is TIIE +<br />
2.76%, which are more favorable terms than those that were negotiated in the original credit agreement.<br />
In or<strong>de</strong>r to reduce our <strong>de</strong>bt, in January <strong>20</strong>12, we completed a series of negotiations with Quitafex, S.A., which resulted in the sale of the capital stock of our Peruvian<br />
subsidiaries, Farmacias Peruana, S.A. and Droguería la Victoria, S.A. The proceeds from this sale will be used to pre-pay the <strong>de</strong>bt and to strengthen our retail pharmacy operations in our<br />
core markets, Chile and Mexico.<br />
34